EGFR and non-small cell lung carcinoma: The EGFR-TKIs, such as gefitinib, erlotinib and icotinib, specifically target EGFR, and has demonstrated a significant survival benefit for NSCLC patients with activating EGFR mutations [4, 6, 39].